Ready-to-drink bowel prep effective in patients with renal impairment, plus more top stories in gastroenterology

Research from Digestive Disease Week dominated the top stories in gastroenterology last week. One study showed that a ready-to-drink solution of sodium picosulfate, magnesium oxide and citric acid was an effective bowel preparation for patients with normal and impaired renal function undergoing a non-emergent colonoscopy.

Another top story was about new data that suggested inflammatory bowel diseases may require more intense management in value-based care programs compared with other chronic gastrointestinal conditions due to higher cost volatility.

Read these and more top stories in gastroenterology below:

Ready-to-drink bowel prep effective in patients with mild, moderate renal impairment

A ready-to-drink solution of sodium picosulfate, magnesium oxide and citric acid had similar efficacy as a bowel preparation among patients with normal and impaired renal function, according to research from Digestive Disease Week (DDW). Read more.

IBD may require more intense care approach due to higher cost volatility

In value-based care programs, inflammatory bowel diseases like Crohn’s disease and ulcerative colitis may require more intense management compared with other chronic gastrointestinal conditions due to much higher cost volatility, according to data from DDW. Read more.

Organized FIT outreach increases CRC screening

An organized outreach program that mailed fecal immunochemical tests directly to patients helped improved colorectal cancer screening rates over multiple years, according to research from DDW. Read more.

Telephone education improved quality in coloscopy bowel preparation

The implementation of a nurse-driven telephone education protocol significantly improved bowel preparation for colonoscopies, according to data from DDW. Read more.

Relistor reduces mortality in patients with opioid-induced constipation

In this exclusive video, Lynn R. Webster, MD, from PRA Health Sciences in Salt Lake City, discusses his study from DDW that explored the impact of Relistor, a mu-opioid receptor agonist, on all-cause mortality in patients with opioid-induced constipation. Read more.